Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment based on Molecular Profiling Clear all

Conditions: Head and Neck Cancer
Interventions: DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Rhinovirus
Interventions: Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care; Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions: Specialized tumor board recommendation, Standard radiation therapy; Other · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 2 more

Conditions: Metastatic Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis; Drug · Biological · Genetic + 1 more
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: panobinostat, fluorouracil, leucovorin calcium, biopsy, reverse transcriptase-polymerase chain reaction, western blotting, laboratory biomarker analysis, gene expression analysis, RNA analysis, polymorphism analysis; Drug · Procedure · Genetic + 1 more
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more

Conditions: Advanced Cancers
Interventions: Tumor Tissue; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer
Interventions: Genetic profiling; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Advanced Cancers
Interventions: Treatment Based on Genetic Mutation, Treatment Based on No Genetic Mutation; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Glioblastoma
Interventions: specialized tumor board recommendation; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain and Central Nervous System Tumors
Interventions: gene expression analysis, microarray analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 10
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Sioux City, Iowa + 3 more

Conditions: Prostate Cancer
Interventions: Prolaris; Behavioral
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: San Diego, California • West Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Kaposi's Sarcoma
Interventions: VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more

Conditions: Metastatic Breast Cancer
Interventions: Approved therapy will be assigned based on molecular profile and RPMA results; Drug
Lead sponsor: Translational Drug Development; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Fairfax, Virginia • Spokane, Washington

Conditions: Solid Tumors, Hematologic Cancers
Interventions: molecular profiling of tumors, Clinical Germline Analysis; Genetic
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 18
States / cities: Bridgeport, Connecticut • Hartford, Connecticut • Norwalk, Connecticut + 13 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 13
States / cities: West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more

Conditions: Lung Cancer, Lymphoma
Interventions: DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Neuroblastoma, Cancer
Interventions: Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib; Procedure · Genetic · Other + 2 more
Lead sponsor: Yael P Mosse; Other
Eligibility: 1 Year to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation; Drug · Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Carcinoma
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, Treatment determined by physician; Drug · Other
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 21
States / cities: Huntsville, Alabama • Fort Myers, Florida • Jacksonville, Florida + 18 more

Conditions: Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy; Procedure · Other · Genetic + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more

Conditions: Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions: Specialized tumor board recommendation; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 21 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions: Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions: Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy; Other · Genetic · Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

Molecular Profiling for Individualized Treatment Plan for DIPG

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Genomic Profiling Assay in Phase I

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Rational Therapeutics Based on Matched Tumor and Normal Tissue

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

Prospective Prolaris Value and Efficacy

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca

Genomic Profiling in Cancer Patients

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Next Generation Personalized Neuroblastoma Therapy

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia